{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:31:32Z","timestamp":1791617492481,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Collaborative Academic Innovation Project of Shandong Cancer Hospital","award":["GF003"],"award-info":[{"award-number":["GF003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15983-7","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:35:09Z","timestamp":1775892909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient-reported outcomes of adjuvant therapy with CDK4\/6 inhibitors for HR+\/HER2- early breast cancer: a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Binbin","family":"Cong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanqiang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changping","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenyou","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongsheng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6252-684X","authenticated-orcid":false,"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"3","key":"15983_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"1","key":"15983_CR2","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353.","journal-title":"J Natl Cancer Cent"},{"issue":"6","key":"15983_CR3","doi-asserted-by":"publisher","first-page":"e2321388","DOI":"10.1001\/jamanetworkopen.2023.21388","volume":"6","author":"J Li","year":"2023","unstructured":"Li J, Zhou J, Wang H, Liu Z, Fan Z, Liu Y, et al. Trends in Disparities and Transitions of Treatment in Patients With Early Breast Cancer in China and the US, 2011 to 2021. JAMA Netw open. 2023;6(6):e2321388.","journal-title":"JAMA Netw open"},{"key":"15983_CR4","doi-asserted-by":"crossref","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5).","DOI":"10.1093\/jnci\/dju055"},{"key":"15983_CR5","doi-asserted-by":"publisher","first-page":"175883592513267","DOI":"10.1177\/17588359251326710","volume":"17","author":"M Hussain","year":"2025","unstructured":"Hussain M, Brezden-Masley C, Chia S, Curigliano G, Webster M, Henning JW. Clinician\u2019s guide: expert insights on the use of CDK4\/6 inhibitors in patients with early breast cancer. Therapeutic Adv Med Oncol. 2025;17:17588359251326710.","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"5","key":"15983_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3322\/caac.21777","volume":"73","author":"LA Huppert","year":"2023","unstructured":"Huppert LA, Gumusay O, Idossa D, Rugo HS. Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. Cancer J Clin. 2023;73(5):480\u2013515.","journal-title":"Cancer J Clin"},{"issue":"21","key":"15983_CR7","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.2217\/fon-2022-0310","volume":"18","author":"KM Sheffield","year":"2022","unstructured":"Sheffield KM, Peachey JR, Method M, Grimes BR, Brown J, Saverno K, et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncol (London England). 2022;18(21):2667\u201382.","journal-title":"Future Oncol (London England)"},{"issue":"5","key":"15983_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Network: JNCCN. 2024;22(5):331\u201357.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"Suppl 6","key":"15983_CR9","doi-asserted-by":"publisher","first-page":"vi25","DOI":"10.1093\/annonc\/mdr372","volume":"22","author":"F Cardoso","year":"2011","unstructured":"Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals oncology: official J Eur Soc Med Oncol. 2011;22(Suppl 6):vi25\u201330.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"6","key":"15983_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","volume":"22","author":"S Goel","year":"2022","unstructured":"Goel S, Bergholz JS, Zhao JJ. Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. 2022;22(6):356\u201372.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"15983_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","volume":"36","author":"GN Hortobagyi","year":"2025","unstructured":"Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. Annals oncology: official J Eur Soc Med Oncol. 2025;36(2):149\u201357.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"1","key":"15983_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77\u201390.","journal-title":"Lancet Oncol"},{"issue":"2","key":"15983_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, Kato T, Majem M, Groh\u00e9 C, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023;389(2):137\u201347.","journal-title":"N Engl J Med"},{"key":"15983_CR14","doi-asserted-by":"publisher","first-page":"e52572","DOI":"10.2196\/52572","volume":"13","author":"RT Jayasinghe","year":"2024","unstructured":"Jayasinghe RT, Ahern S, Maharaj AD, Romero L, Ruseckaite R. Identifying Existing Guidelines, Frameworks, Checklists, and Recommendations for Implementing Patient-Reported Outcome Measures: Protocol for a Scoping Review. JMIR Res protocols. 2024;13:e52572.","journal-title":"JMIR Res protocols"},{"key":"15983_CR15","doi-asserted-by":"publisher","first-page":"107327482311683","DOI":"10.1177\/10732748231168318","volume":"30","author":"Z Heidary","year":"2023","unstructured":"Heidary Z, Ghaemi M, Hossein Rashidi B, Kohandel Gargari O, Montazeri A. Quality of Life in Breast Cancer Patients: A Systematic Review of the Qualitative Studies. Cancer control: J Moffitt Cancer Cent. 2023;30:10732748231168318.","journal-title":"Cancer control: J Moffitt Cancer Cent"},{"issue":"4","key":"15983_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.annonc.2021.12.010","volume":"33","author":"E Minvielle","year":"2022","unstructured":"Minvielle E, di Palma M, Mir O, Scott\u00e9 F. The use of patient-reported outcomes (PROs) in cancer care: a realistic strategy. Annals oncology: official J Eur Soc Med Oncol. 2022;33(4):357\u20139.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"6","key":"15983_CR17","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1002\/cai2.141","volume":"3","author":"F Ma","year":"2024","unstructured":"Ma F, Yan X, Guan X, Liu T. Development and validation of the NCC-BC-A scale to assess patient-reported outcomes for breast cancer patients in China. Cancer Innov. 2024;3(6):e141.","journal-title":"Cancer Innov"},{"issue":"10","key":"15983_CR18","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual life research: Int J Qual life aspects Treat care rehabilitation. 2011;20(10):1727\u201336.","journal-title":"Qual life research: Int J Qual life aspects Treat care rehabilitation"},{"issue":"1","key":"15983_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target therapy. 2025;10(1):49.","journal-title":"Signal Transduct Target therapy"},{"key":"15983_CR20","doi-asserted-by":"publisher","first-page":"175883592094306","DOI":"10.1177\/1758835920943065","volume":"12","author":"N Harbeck","year":"2020","unstructured":"Harbeck N, Franke F, Villanueva-Vazquez R, Lu YS, Tripathy D, Chow L, et al. Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). Therapeutic Adv Med Oncol. 2020;12:1758835920943065.","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"2","key":"15983_CR21","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1634\/theoncologist.2019-0551","volume":"25","author":"PA Kaufman","year":"2020","unstructured":"Kaufman PA, Toi M, Neven P, Sohn J, Grischke EM, Andre V, et al. Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. Oncologist. 2020;25(2):e243\u201351.","journal-title":"Oncologist"},{"issue":"2","key":"15983_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40265-024-02144-y","volume":"85","author":"EV Klocker","year":"2025","unstructured":"Klocker EV, Egle D, Bartsch R, Rinnerthaler G, Gnant M. Efficacy and Safety of CDK4\/6 Inhibitors: A Focus on HR+\/HER2- Early Breast Cancer. Drugs. 2025;85(2):149\u201369.","journal-title":"Drugs"},{"issue":"2","key":"15983_CR23","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.clbc.2024.08.022","volume":"25","author":"Y Kanjanapan","year":"2025","unstructured":"Kanjanapan Y, Anderson W, Smith M, Green J, Chalker E, Craft P. Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4\/6 Inhibitors. Clin Breast Cancer. 2025;25(2):e159\u2013e. 69.e2.","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"15983_CR24","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/1078-0432.CCR-24-1724","volume":"31","author":"PA Fasching","year":"2025","unstructured":"Fasching PA, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, et al. Health-Related Quality of Life in Patients with HR+\/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial. Clin cancer research: official J Am Association Cancer Res. 2025;31(9):1625\u201335.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"15983_CR25","doi-asserted-by":"crossref","unstructured":"Tolaney SM, Guarneri V, Seo JH, Cruz J, Abreu MH, Takahashi M et al. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer. European journal of cancer (Oxford, England: 1990). 2024;199:113555.","DOI":"10.1016\/j.ejca.2024.113555"},{"key":"15983_CR26","unstructured":"Ge R, Wang BY, Jiang ZF. [Expert consensus on the management of adverse events of CDK4\/6 inhibitors in breast cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2022;44(12):1296\u2013304."},{"issue":"6","key":"15983_CR27","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.annonc.2022.03.006","volume":"33","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, O\u2019Shaughnessy J, Boyle F, Toi M, Broom R, Blancas I, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Annals oncology: official J Eur Soc Med Oncol. 2022;33(6):616\u201327.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"1","key":"15983_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/10781552241279189","volume":"31","author":"T Drowne","year":"2025","unstructured":"Drowne T, Armgardt E, Svoboda A. Real-world experience of abemaciclib for adjuvant and metastatic breast cancer. J Oncol Pharm practice: official publication Int Soc Oncol Pharm Practitioners. 2025;31(1):141\u20136.","journal-title":"J Oncol Pharm practice: official publication Int Soc Oncol Pharm Practitioners"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15983-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15983-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15983-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:49:21Z","timestamp":1779414561000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15983-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15983"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15983-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of Shandong First Medical University Affiliated Cancer Hospital (Ethics No. SDC202503003), and written informed consent was obtained from all participants prior to enrollment. This study was conducted in accordance with the principles of the Declaration of Helsinki (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"668"}}